Assessing the Safety of Biological Medicines, Biosimilars and Advanced Therapies throughout the Product Lifecycle
The joint BIA/MHRA conference will provide the opportunity for organisations involved in the development of biopharmaceuticals, as well as regulators and service providers, to gain insights on the management of safety issues from industry colleagues and senior experts at UK and European regulatory agencies. The conference will discuss the approach to safety throughout the life cycle and will provide an update on changes to the EU pharmacovigilance system.
This event co-chaired by Dr Ian Hudson, Director of Licensing Division, MHRA, and Member of EMA’s Committee for Medicinal Products for Human Use (CHMP), and Alan Morrison, Chairman of BIA Regulatory Affairs Advisory Committee; Vice President, International Regulatory Affairs and Safety, Amgen, is the ideal place for networking and will bring those involved in regulating and developing these products together to discuss solutions to the challenges in this important area of medicine regulation.
